MedTrace Logo

A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers

NCT06523803 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2025-10-21

No results posted yet for this study

Summary

This study is being done to find out if ZW171 is safe and can treat participants with advanced (locally advanced \[inoperable\] and/or metastatic) mesothelin-expressing cancers.

Conditions

  • Mesothelin-expressing Advanced Cancers

Interventions

DRUG

ZW171

Administered per protocol requirements

Sponsors & Collaborators

  • Zymeworks BC Inc.

    lead INDUSTRY

Principal Investigators

  • Pranshul Chauhan, MSc, MB, BCh, BAO · Zymeworks BC Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-30
Primary Completion
2025-09-30
Completion
2025-10-01
FDA Drug
Yes

Countries

  • United States
  • Germany
  • South Korea
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06523803 on ClinicalTrials.gov